The gut microbiota - A clinical perspective on lessons learned

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 10, 2012, Pages 609-614

  Shanahan, Fergus ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BACTERIAL ANTIGEN; BACTERIOCIN; BIOLOGICAL PRODUCT; INTERLEUKIN 10; POLYPEPTIDE ANTIBIOTIC AGENT; POLYSACCHARIDE; PREBIOTIC AGENT; PROBIOTIC AGENT; PROINSULIN; SHORT CHAIN FATTY ACID; TRANSFORMING GROWTH FACTOR BETA1; VACCINE; VITAMIN;

ALLERGIC ASTHMA; ALLERGIC DISEASE; AUTOIMMUNE DISEASE; BACILLUS THURINGIENSIS; BACTERIAL VIRULENCE; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CROHN DISEASE; DIABETES MELLITUS; DIET THERAPY; DIETARY INTAKE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ACTIVITY; DISEASE COURSE; DRUG MISUSE; ENTERITIS; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE FLORA; METABOLIC DISORDER; MICROBIAL DIVERSITY; MICROBIAL METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYMBIOSIS; ULCERATIVE COLITIS;

DIET; GASTROINTESTINAL TRACT; HUMANS; LIFE STYLE; METABOLOMICS; METAGENOME; RISK FACTORS;

EID: 84867214356     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.145     Document Type: Review

References (37)

1. Venter, J. C. A Life Decoded. 3 (Penguin, Allen Lane, London, 2007).
2. Clemente, J. C., Ursell, L. K., Parfrey, L. W. & Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 148, 1258-1270 (2012).
3. Cho, I. & Blaser, M. J. The human microbiome: At the interface of health and disease. Nat. Rev. Genet. 13, 260-270 (2012).
4. Shanahan, F. The gut microbiota in 2011: Translating the microbiota to medicine. Nat. Rev. Gastroenterol. Hepatol. 9, 72-74 (2012).
5. Bernstein, C. N. & Shanahan, F. Disorders of a modern lifestyle: Reconciling the epidemiology of inflammatory bowel diseases. Gut 57, 1185-1191 (2008).
6. Hviid, A., Svanström, H. & Frisch, M. Antibiotic use in inflammatory bowel diseases in childhood. Gut 60, 49-54 (2011).
7. Shaw, S. Y., Blanchard, J. F. & Bernstein, C. N. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am. J. Gastroenterol. 105, 2687-2692 (2010).
8. Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L. & Gordon, J. I. Human nutrition, the gut microbiome and the immune system. Nature 474, 327-336 (2011).
9. Shoda, R., Matsueda, K., Yamato, S. & Umeda, N. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n 6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am. J. Clin. Nutr. 63, 741-745 (1996).
10. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011).
11. Brandl, K. et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 455, 804-807 (2008).
12. Vijay-Kumar, M. et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 228-231 (2010).
13. Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745-757 (2011).
14. Shulzhenko, N. et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat. Med. 17, 1585-1593 (2011).
15. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).
16. Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179-185 (2012).
17. Wall, R. et al. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am. J. Clin. Nutr. 89, 1389-1401 (2009).
18. Murphy, E. F. et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut http://dx.doi.org/10.1136/gutjnl-2011-300705.
19. Round, J. L. et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332, 974-977 (2011).
20. Franchi, L. et al. NLRC-driven production of IL 1ß discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13, 449-456 (2012).
21. Blander, J. M. & Sander, L. E. Beyond pattern recognition: Five immune checkpoints for scaling the microbial threat. Nat. Rev. Immunol. 12, 215-225 (2012).
22. Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831-835 (2010).
23. Lewis, K. Recover the lost art of drug discovery. Nature 485, 439-440 (2012).
24. Rea, M. C. et al. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 4639-4644 (2011).
25. Kelly, C. P. & LaMont, J. T. Clostridium difficile - more difficult than ever. N. Engl. J. Med. 359, 1932-1940 (2008).
26. Im, G. Y. et al. The appendix may protect against Clostridium difficile recurrence. Clin. Gastroenterol. Hepatol. 9, 1072-1077 (2011).
27. Hamilton, M. J., Weingarden, A. R., Sadowsky, M. J. & Khoruts, A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenerol. 107, 761-767 (2012).
28. Shanahan, F. Probiotics in perspective. Gastroenterology 139, 1808-1812 (2010).
29. Benezra, A., DeStefano, J. & Gordan, J. I. Anthropology of microbes. Proc. Natl Acad. Sci. USA 109, 6378-6381 (2012).
30. Cadwell, K. et al. Virus plus susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 141, 1135-1145 (2010).
31. Kuss, S. K. et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 334, 249-252 (2011).
32. Virgin, H. V. & Todd, J. A. Metagenomics and personalised medicine. Cell 147, 44-56 (2011).
33. Macho Fernandez, E. et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 60, 1050-1059 (2011).
34. Yan, F. & Polk, D. B. Characterization of a probiotic-derived soluble protein which reveals a mechanism of preventive and treatment effects of probiotics on intestinal inflammatory diseases. Gut Microbes 3, 25-28 (2012).
35. Takiishi, T. et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Invest. 122, 1717-1725 (2012).
36. Hamady, Z. Z. et al. Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF ß1 under control of dietary zylan 1. Inflamm. Bowel Dis. 17, 1925-1935 (2011).
37. Shanahan, F. Gut microbes: From bugs to drugs. Am. J. Gastroenterol. 105, 275-279 (2010).